Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

An expert explained how a patient’s own T cells can be extracted, manufactured and infused back into the body as a treatment ...

Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.

1. The infrastructure for growth is coming together quickly Iovance's first cell therapy product, Amtagvi, is a bit complicated to manufacture and administer. Amtagvi treats melanoma using a ...

Amtagvi Infusions: A total of 146 patients have been infused with Amtagvi since the first commercial infusion in April 2024, including 25 patients infused in the second quarter, 82 patients infused in ...

JMP Securities analyst Reni Benjamin has reiterated their bullish stance on IOVA stock, giving a Buy rating on November 8. Reni Benjamin has ...

Dr. Fred Vogt, our Interim Chief Executive Officer and President will provide an introduction and summarize the latest progress with our U.S. Commercial launch of Amtagvi, including revenue and ...

Iovance Biotherapeutics (NASDAQ: IOVA) is going to finish the week strong on the stock market if its Thursday performance is ...

Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue FY24 and FY25 Total Product Revenue Guidance: Amtagvi adoption is on track to continue ...